JP2021075563A5 - - Google Patents

Download PDF

Info

Publication number
JP2021075563A5
JP2021075563A5 JP2021020446A JP2021020446A JP2021075563A5 JP 2021075563 A5 JP2021075563 A5 JP 2021075563A5 JP 2021020446 A JP2021020446 A JP 2021020446A JP 2021020446 A JP2021020446 A JP 2021020446A JP 2021075563 A5 JP2021075563 A5 JP 2021075563A5
Authority
JP
Japan
Prior art keywords
composition
oxo
composition according
fibrosis
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021020446A
Other languages
English (en)
Other versions
JP2021075563A (ja
JP7229285B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021075563A publication Critical patent/JP2021075563A/ja
Publication of JP2021075563A5 publication Critical patent/JP2021075563A5/ja
Priority to JP2023020423A priority Critical patent/JP2023065454A/ja
Application granted granted Critical
Publication of JP7229285B2 publication Critical patent/JP7229285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (11)

  1. （５Ｚ，８Ｚ，１１Ｚ，１３Ｅ，１７Ｚ）−１５−オキソイコサ−５，８，１１，１３，１７−ペンタエン酸（「１５−オキソ−ＥＰＡ」）を含む組成物であって、該１５−オキソ−ＥＰＡが、該組成物の総重量の約０．１重量％〜約９９重量％の量で該組成物中に存在する、前記組成物。
  2. （８Ｚ，１１Ｚ，１３Ｅ）−１５−オキソイコサ−８，１１，１３−トリエン酸（「１５−オキソ−ＤＧＬＡ」）を含む組成物であって、該１５−オキソ−ＤＧＬＡが、該組成物の総重量の約０．１重量％〜約９９重量％の量で該組成物中に存在する、前記組成物。
  3. 対象において線維症、炎症、腎臓病、または腎機能障害を治療及び／または予防するための組成物であって、請求項１または２に記載の組成物を含む、前記組成物。
  4. 前記線維症は、肺、肝臓、心臓、縦隔、骨髄、後腹膜腔、皮膚、腸、関節、生殖器、及びこれらの組み合わせからなる群から選択される臓器または組織と関連する、請求項３に記載の組成物。
  5. 前記線維症は、肝線維症である、請求項３または４に記載の組成物。
  6. 前記線維症は、非アルコール性脂肪性肝疾患（ＮＡＦＬＤ）と関連する、請求項３〜５のいずれか１項に記載の組成物。
  7. 前記組成物が、経口投与用に製剤化されている、請求項１または２に記載の組成物。
  8. 前記１５−オキソ−ＥＰＡまたは前記１５−オキソ−ＤＧＬＡは、前記組成物中の唯一の活性成分である、請求項１〜７のいずれか１項に記載の組成物。
  9. 前記組成物は、前記線維症療法に影響を及ぼすための追加の薬剤をさらに含む、請求項１〜８のいずれか１項に記載の組成物。
  10. 前記１５−オキソ−ＥＰＡまたは前記１５−オキソ−ＤＧＬＡは、遊離酸形態である、請求項１〜９のいずれか１項に記載の組成物。
  11. 前記１５−オキソ−ＥＰＡまたは前記１５−オキソ−ＤＧＬＡは、エステル化形態であり、
    任意に、前記エステル化形態は、アルキルエステル形態であり、
    任意に、前記エステル化形態は、トリグリセリド形態である、請求項１〜９のいずれか１項に記載の組成物。
JP2021020446A 2015-05-13 2021-02-12 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 Active JP7229285B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023020423A JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160863P 2015-05-13 2015-05-13
US62/160,863 2015-05-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017559093A Division JP2018524274A (ja) 2015-05-13 2016-05-12 １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020423A Division JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Publications (3)

Publication Number Publication Date
JP2021075563A JP2021075563A (ja) 2021-05-20
JP2021075563A5 true JP2021075563A5 (ja) 2022-01-11
JP7229285B2 JP7229285B2 (ja) 2023-02-27

Family

ID=56131573

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017559093A Pending JP2018524274A (ja) 2015-05-13 2016-05-12 １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2021020446A Active JP7229285B2 (ja) 2015-05-13 2021-02-12 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2023020423A Pending JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017559093A Pending JP2018524274A (ja) 2015-05-13 2016-05-12 １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023020423A Pending JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Country Status (7)

Country Link
US (4) US10047033B2 (ja)
EP (1) EP3294282A1 (ja)
JP (3) JP2018524274A (ja)
CN (3) CN113896628A (ja)
HK (1) HK1250345A1 (ja)
MA (1) MA47141A (ja)
WO (1) WO2016181221A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151825B1 (en) 2014-06-04 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
EP3389647B1 (en) 2015-12-18 2023-04-05 Afimmune Limited Compositions comprising 15-hepe
EP3866759A1 (en) * 2018-10-18 2021-08-25 DS Biopharma Limited Dgla and/or 15-hetre for treating inflammatory, fibrotic, and proliferative conditions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
WO1990014824A1 (en) 1988-01-14 1990-12-13 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of eczema
CA1334002C (en) 1988-09-28 1995-01-17 Barry D. Sears Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
DE4238869C2 (de) 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
DE69407949T2 (de) 1993-10-01 1998-05-14 Scherer Corp R P Zusammensetzungen zum verteilen von duftstoffen
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
CN1951899B (zh) 2000-02-16 2012-02-01 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
JP2002047176A (ja) 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd ＩｇＥ産生抑制剤
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
PL364093A1 (en) 2001-05-30 2004-12-13 Laxdale Limited Coenzyme q (ubiquinone) and eicosapentaenoic acid (epa)
JP2003155233A (ja) 2001-11-16 2003-05-27 Idemitsu Technofine Co Ltd 塗布剤
AU2003284617A1 (en) 2002-11-22 2004-06-18 Nippon Suisan Kaisha, Ltd. Composition containing organic substance having double bond with improved oxidation stability
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
MX2007000208A (es) 2004-07-01 2007-08-07 Schepens Eye Res Inst Composiciones y metodos para tratar trastornos y condiciones del ojo.
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
CA2599112C (en) 2005-02-14 2013-10-22 Suntory Limited Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JPWO2009154230A1 (ja) 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
PT2800563T (pt) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Composições enriquecidas com dpa de ácidos gordos omega-3 polinsaturados sob a forma de ácido livre
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
US20150079164A1 (en) 2012-04-04 2015-03-19 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
SG11201504641SA (en) 2012-12-24 2015-07-30 Qualitas Health Ltd Eicosapentaenoic acid (epa) formulations
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
EP3151825B1 (en) 2014-06-04 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
EP3389647B1 (en) 2015-12-18 2023-04-05 Afimmune Limited Compositions comprising 15-hepe
CA3027867A1 (en) 2016-01-07 2017-07-13 Ds Biopharma Limited Pharmaceutical compositions comprising dgla and use of same

Similar Documents

Publication Publication Date Title
JP2021075563A5 (ja)
JP2023065454A5 (ja)
JP2001511768A (ja) 活性型ビタミンｄ類似体を使用した前立腺疾患の治療方法
JP2015508068A5 (ja)
US6426367B1 (en) Methods for selectively occluding blood supplies to neoplasias
Durando et al. Pneumopericardium in a horse secondary to sternal bone marrow aspiration
DE60301878T2 (de) Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz
AU2021203189A1 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
MILLER et al. Pyopneumopericardium attributed to an esophagopericardial fistula: report of a survivor and review of the literature
Vineberg Restoration of coronary circulation by anastomosis
RU2013126522A (ru) Лизурид, тергурид и их производные для применения в профилактике и/или лечении фиброзных изменений
Lowry et al. Primary osteosarcoma of the heart
KR100874626B1 (ko) 담즙 분비 촉진 조성물
JP2013209429A (ja) 慢性閉塞性肺疾患を処置するための方法および組成物
JPS5931789A (ja) １−ヒドロキシ−３−アミノプロパン−１，１−ジホスホン酸のゲル様カルシウム塩
Sutcliffe et al. Chronic granulomatous disease
US9636352B2 (en) Compositions and methods for the treatment of musculoskeletal related diseases and disorders using metal ion-citrate analog complexes
Jugdutt et al. Hepatic artery ligation in treatment of carcinoid syndrome.
ZEPPA et al. Medial degeneration and aneurysm of the hepatic artery
Dreizen et al. The effect of experimentally induced generalized medial arteriosclerosis on the oral vessels of the rat
JP2005523317A (ja) 爪の微生物病を制御するための局所用組成物の使用
JP2007504097A5 (ja)
JP2011505408A (ja) ３−（２，２，２−トリメチルヒドラジニウム）プロピオナートのフマル酸水素塩及びリン酸二水素塩を医療に用いる方法
WO1999018968A1 (fr) Inhibiteur de l'hypertension portale
JPS63211231A (ja) 雄性不妊動物の治療剤